HOXA10 and breast carcinoma: Therefore, we suggest that the prognostic model using the HOXA9 and HOXA10 promoter CpG combination has translational potential to facilitate determination of breast cancer prognosis and therapeutic strategies targeting a specific molecular regulation module.